Press Releases

TORONTO, ONTARIO -- (MARKET WIRE) -- 02/09/12 -- As the February 29th deadline approaches to make a contribution to a Registered Retirement Savings Plan (RRSP) and as part of its ongoing commitment to improving financial literacy, BMO Financial Group will be providing daily retirement tips during the month of February from BMO Retirement Institute Head Tina Di Vito's new book 52 Ways To Wreck Your Retirement...And How To Rescue It.

Tip Number Seventeen:

Be wary of using credit cards as a long-term loan solution

An easy way to wreck your retirement is to incur interest charges on credit card balances. To minimize interest costs and maximize savings, understand the rates and fees associated with your credit card, such as interest charges, annual fees, cash advance fees and foreign exchange charges, and effectively manage your purchases and payments. Also, take advantage of rewards programs offered in conjunction with your credit card.

Avoid charging items that you can't afford to pay off quickly as monthly interest charges can end up costing you a lot more than the original price of the item. Instead, save for the item beforehand and pay off the balance/charge by the due date to avoid additional charges.

Tip Number Eighteen:

Take advantage of employee benefits and save more money for retirement

Do not make the mistake of thinking you are alone in saving for retirement. Many employers offer registered pension plans such as a Defined Contribution pension plan (DC), Defined Benefit pension plan (DB) or a group RRSP, that match employee contributions. This is essentially free money that can easily double the amount of pension savings you accumulate.

Also, take full advantage of employee benefits such as insurance programs, dental and health care coverage, stock purchase plans, employee assistance programs and employee discounts. These are services that you do not have to pay for yourself and they will end up helping you save more money that you can allocate to your retirement or use to pay off debts.

For more information on retirement: www.bmo.com/retirement.

Get the latest BMO press releases via Twitter by following @BMOmedia.

Contacts:
For all news media enquiries please contact:
Rachael McKay, Toronto
416-867-3996
rachael.mckay@bmo.com

Sarah Bensadoun, Montreal
514-877-8224
sarah.bensadoun@bmo.com

Laurie Grant, Vancouver
604-665-7596
laurie.grant@bmo.com

Source: BMO Financial Group and BMO Bank of Montreal

-- Mark Alles, Chief Commercial Officer for Celgene Corporation, to Become an Acetylon Board Observer --

BOSTON--(BUSINESS WIRE)-- Acetylon Pharmaceuticals today announced that Celgene Corporation (NASDAQ: CELG) will invest a total of $15 million in Acetylon via the purchase of Series B-2 Preferred Stock. Mark Alles, Celgene’s Chief Commercial Officer will serve as a non-voting observer to the Acetylon Board of Directors. Celgene does not receive rights or options to Acetylon technology under the terms of the equity purchase agreements.

“Our investment in Acetylon Pharmaceuticals reflects our continuing commitment to help patients with hematologic malignancies to gain access to disease-altering therapies that improve the lives of patients worldwide,” stated Mr. Alles. “Acetylon has established itself as the leader in developing next generation, selective HDAC inhibitors for cancers as well as non-cancer disease indications and we believe the Company’s approach could significantly benefit patients.”

“Celgene is a leader in developing and delivering transformational therapies for the treatment of blood cancers, and their investment in Acetylon further validates the rapid progress and therapeutic promise of our selective HDAC inhibitor drug development programs,” commented Walter C. Ogier, President and Chief Executive Officer of Acetylon. “The potential synergistic combination of Celgene’s class-leading myeloma drug, Revlimid® (lenalidomide), with Acetylon’s selective HDAC6 inhibitor, ACY-1215™, in clinical trials is an exciting prospect for the treatment of patients with progressive disease. In addition to Celgene’s funding, we will also welcome their contribution of clinical and commercialization expertise to our organization as we advance and expand our clinical trials program over the coming year.”

Acetylon is currently focused on the development of potential drug candidates based on next-generation Class II-selective histone deacetylase (HDAC) inhibitors. The Class IIB enzyme, HDAC6, has emerged as an important target in inflammatory disease, neurologic disease and broadly in cancer. Acetylon Pharmaceuticals believes that its next-generation, selective HDAC inhibitor compounds may accomplish enhanced clinical utility by reducing or eliminating the debilitating and sometimes life-threatening side effects associated with the current first-generation of non-selective HDAC inhibitors and providing enhanced disease response and patient outcomes.

About HDAC6 Inhibition

Acetylon’s lead HDAC6 inhibitor program is focused on enhancing drug potency and reducing or eliminating side effects common to HDAC inhibition through highly selective targeting of the HDAC6 enzyme. Inhibition of HDAC6 versus other isoforms uniquely preserves normal gene expression in cells, thereby minimizing patient toxicity. At the same time, HDAC6 inhibition severely disrupts diseased cells’ ability to produce normal proteins, through disruption of the HSP-90 protein chaperone system and to dispose of damaged misfolded proteins through modification of microtubules and disruption of the aggresome protein disposal pathway. Metabolically active cancer and autoimmune cells produce large amounts of misfolded proteins and inhibition of HDAC6 further increases the generation and accumulation of protein “trash”, triggering self-destruction of diseased cells via programmed cell death and leading to regression of disease.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at www.celgene.com.

About Acetylon Pharmaceuticals, Inc.

Acetylon Pharmaceuticals, Inc. is applying its unique capabilities to discover and develop next-generation, highly selective small molecule drugs to realize the therapeutic potential of HDAC inhibition to treat cancer, autoimmune and other diseases, while reducing the side effects common to this class of drugs. The Company is located in Boston and is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University. www.acetylon.com

Acetylon Pharmaceuticals, Inc.Walter C. Ogier, 617-638-0460President and Chief Executive Officerwogier@acetylon.comorMedia:MacDougall Biomedical CommunicationsKari Watson, 781-235-3060Senior Vice Presidentkwatson@macbiocom.com

Source: Acetylon Pharmaceuticals, Inc.

MIAMI--(BUSINESS WIRE)-- Ryder System, Inc. (NYSE: R) Chairman and Chief Executive Officer Greg Swienton will present a Company update at the 27th Annual BB&T Capital Markets Transportation Services Conference.

About Ryder

Ryder is a FORTUNE 500® commercial transportation, logistics and supply chain management solutions company. Ryder’s stock (NYSE: R) is a component of the Dow Jones Transportation Average and the Standard & Poor’s 500 Index. Inbound Logistics magazine has recognized Ryder as a top third party logistics provider and included Ryder in its 2011 and 2010 “Green Partners” listing. Ryder has also been ranked two years in a row as one of the top 250 U.S. companies in the Newsweek Green Rankings. In addition, Security Magazine has named Ryder one of the top companies for security practices in the transportation, logistics, supply chain, and warehousing sector. Ryder is a proud member of the American Red Cross Annual Disaster Giving Program, supporting national and local disaster preparedness and response efforts. For more information, visit www.ryder.com and follow us on Facebook, YouTube, and Twitter.

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Ryder System, Inc.David Bruce, 305-500-4999David_Bruce@Ryder.comorBob Brunn, 305-500-4210Bob_S_Brunn@Ryder.com

Source: Ryder System, Inc.

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- OCEG, a nonprofit think tank, has released version 2.1 of its GRC Capability Model (“the Red Book”), which contains open source standards that organizations may use to improve governance, management and assurance of performance, risk and compliance plans and actions.

“This update to the Red Book has benefitted from the input of hundreds of experts in the drafting of earlier versions, and from feedback provided by organizations that have applied it over the past eight years,” says OCEG Chair Scott L. Mitchell. “With this revision, we clarify the integrated relationship between risk, compliance and performance management, and the governance, assurance and management of each.”

“We have also provided an open source share and share alike license for the Red Book,” says OCEG President Carole Switzer, “which allows anyone to use and build upon the Red Book with open source expansions. This means, for example, that a company may import the standards into any software solution they want to use, or may build training materials around the standards. Not only that, but anyone may download a copy of the Red Book for free from the OCEG website.”

“The free and open source nature of the Red Book sets it apart from many other standards, which must be purchased for each use,” says Mr. Mitchell, “and we hope that this model will be considered and followed by other standard issuing organizations.”

The OCEG Red Book is available for download at www.oceg.org/standards. Hard copies or spreadsheet versions may be purchased through the OCEG online store at www.oceg.org/catalog/standards-and-guides. A companion resource, the GRC Assessment Toolkit, is also available through the store.

OCEGCarole Switzer, 520-232-0952cswitzer@oceg.org

Source: OCEG